

A North American company focused on providing gastroenterologists (“GIs”) with innovative products and services for the diagnosis and treatment of gastrointestinal diseases.

CAPITAL STRUCTURE

at June 30, 2017

Issued and OS Shares: 74.1 Million
Fully Diluted Shares: 75.7 Million

MARKET CAPITAL

at August 2, 2017

CDN\$340.9 Million
US\$270.5 Million

3-Month Average Daily Trading Volume

TSX: 414,643 shares
NYSE MKT: 153,028 shares

FINANCIAL STRENGTH

at June 30, 2017

\$7.8 Million cash and cash equivalents

\$57.3 Million available under Scotia debt facility at approximately 3.25% interest

\$42.7 Million in total debt

GASTROENTEROLOGY FACTS

- Routine colonoscopies for individuals +50 is the US standard of care for early detection of colon cancer
- +15 million endoscopic procedures are performed in the US annually
- Roughly 50% of endoscopic procedures are anesthesia-assisted
- Approximately 800-1,000 GI-specific Ambulatory Surgical Centres (“ASCs”)
- Approximately 10.4 million people suffer from hemorrhoids in the US (According to the National Institute of Diabetes & Digestive & Kidney Diseases)

Our goal is to be the trusted partner for the GI community and the preeminent provider of GI anesthesia in the US.



CRH ORegan System®

Non-Surgical Hemorrhoid Treatment
Fast. Painless. Proven.


- Single-use, disposable banding system for hemorrhoid treatment
- Paradigm shift for GI’s in the US
- Turnkey package includes training protocols, product, and operational + marketing expertise
- Utilized in all lower 48 US states
- Q2 2017 adjusted operating EBITDA margin: 59%
- Trained ~2,653 GIs in ~985 GI private practices (at June 30, 2017)

CRH Anesthesia Management

- Anesthesia services for upper and lower endoscopic procedures performed by GIs in Ambulatory Surgical Centers (“ASCs”)
- First transaction in December 2014; 12 more transactions completed since then for total investment of \$140.4 Million
- Q2 2017 adjusted operating EBITDA margin: 51%
- Servicing 28 ASCs in 7 states and performing ~195,000 procedures annually (at August 2, 2017)

Strong Financial Performance

Revenue & Adjusted Operating EBITDA⁽¹⁾



⁽¹⁾Total Operating EBITDA is a non-IFRS measure defined as operating income before interest, taxes, depreciation, and related expenses, amortization, stock-based compensation, acquisition-related expenses, and asset impairment charges. Refer to the end of the Company's most recent Financial Report for a reconciliation of reported financial results to non-IFRS measures.

WHY INVEST IN CRH

- ✓ Strong relationships with GI community built through O'Regan System's direct-to-physician model
- ✓ Scalable GI anesthesia national growth strategy. Approximately 800 - 1,000 GI-focused ASCs in the US
- ✓ Leveraging large pool of GI anesthesia acquisition targets
- ✓ Cash flow positive since 2008 and generating approximately \$6M in quarterly cash flow to fund organically-driven acquisition growth
- ✓ Credit facility provides additional financial capacity to invest in anesthesia growth at low interest rate

EXECUTIVE MANAGEMENT

Edward Wright – CEO – *Established CRH's direct-to-physician model to introduce the O'Regan system to the GI community. Leveraged CRH's excellent relationships to launch CRH Anesthesia. Over 10 years experience in health care.*

Richard Bear – CFO – *Has planned and executed all of CRH's financial transactions, including capital private placements debt facilities and all of CRH Anesthesia's transactions.*

Jay Kreger, President CRH Anesthesia – *Formerly VP of Development for the ASC division of HCA. Extensive experience in business development and operations.*

BOARD OF DIRECTORS

Tony Holler, Chairman

David Johnston, Independent

Todd Patrick, Independent

Ian Webb, Independent

Edward Wright, CEO

Legal Disclaimer: This document refers to some non-IFRS financial measures as supplemental indicators of our financial and operating performance. These non-IFRS measures include Operating EBITDA. The Company believes that supplementary indicators reflect the Company's ongoing business in a manner that allows for meaningful period-to-period comparisons and analysis of trends in its business. Please refer to the Company's report for the three months ended June 30, 2017 available at <http://investors.crhsystem.com/> for a reconciliation of these non-IFRS measures. This document may contain forward-looking statements that may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance or achievements to differ materially from the future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements reflect current expectations of management regarding future events and operating performance as of the date of this document. The Company bases its forward-looking statements on information currently available to it and assumes no obligation to update them, other than as required by law. Please refer to the Company's latest Financial Report and Annual Information Form, available on SEDAR at www.sedar.com and our website at <http://investors.crhsystem.com/> for a list of risks related to our business.